ABI-274

• Description :

  ABI-274 is a tubulin and colchicine binding site inhibitor. ABI-274 significantly promotes cancer cell apoptosis in vitro when combined with vemurafenib (HY-12057) . ABI-274 exhibits potent synergistic efficacy in the vemurafenib-resistant xenograft model in nude mice. ABI-274 can be studied in research on melanoma[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Microtubule/Tubulin

• Related Pathways :

  Cell Cycle/DNA Damage; Cytoskeleton

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Smiles :

  COC1=CC(C(C2=CN=C(C3=CC=C(C=C3)C)N2)=O)=CC(OC)=C1OC

• Molecular Formula :

  C20H20N2O4

• Molecular Weight :

  352.38

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Wang, J., et al., (2014) . Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. Molecular cancer therapeutics, 13 (1), 16-26.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1253697-93-6]